AI Article Synopsis

  • Glycoengineering allowed Pichia pastoris to produce proteins with human-like N-linked sugars for creating monoclonal antibodies.
  • The research focused on optimizing various process parameters using a design of experiments approach, resulting in a yield of up to 1.6 g/L of monoclonal antibodies.
  • The process was successfully scaled from 30-L to 1,200-L while maintaining product quality and productivity, proving its commercial viability.

Article Abstract

Glycoengineering enabled the production of proteins with human N-linked glycans by Pichia pastoris. This study used a glycoengineered P. pastoris strain which is capable of producing humanized glycoprotein with terminal galactose for monoclonal antibody production. A design of experiments approach was used to optimize the process parameters. Followed by further optimization of the specific methanol feed rate, induction duration, and the initial induction biomass, the resulting process yielded up to 1.6 g/L of monoclonal antibody. This process was also scaled-up to 1,200-L scale, and the process profiles, productivity, and product quality were comparable with 30-L scale. The successful scale-up demonstrated that this glycoengineered P. pastoris fermentation process is a robust and commercially viable process.

Download full-text PDF

Source
http://dx.doi.org/10.1002/btpr.695DOI Listing

Publication Analysis

Top Keywords

pichia pastoris
8
antibody production
8
glycoengineered pastoris
8
monoclonal antibody
8
process
7
optimization glycoengineered
4
glycoengineered pichia
4
pastoris
4
pastoris cultivation
4
cultivation process
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!